Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. NAMSW.NASDAQ

NewAmsterdam Pharma Company N.V. Warrant (NAMSW NASDAQ) stock market data APIs

$8.92 0.22(2.5%) as of July 26, 2024
Price chart is built with Anychart

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V. Warrant Financial Data Overview

8.7
8.92
-
8.92
8.6
0.99-14.67
0
0
6 862 K
0.011
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NAMSW',
Type: 'Common Stock',
Name: 'NewAmsterdam Pharma Company N.V. Warrant',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG01BNP2MK0',
ISIN: NULL,
CUSIP: NULL,
CIK: '1936258',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2022-11-23',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Warrant',
IsDelisted: false,
}

NewAmsterdam Pharma Company N.V. Warrant Fundamental Data is available in our Financial Data APIs

  • Net Revenue 6 862 K
  • EBITDA -198 540 992
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get NewAmsterdam Pharma Company N.V. Warrant Earnings via APIs

  • Latest Release NaN
  • EPS/Forecast NaN

Get NewAmsterdam Pharma Company N.V. Warrant End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get NewAmsterdam Pharma Company N.V. Warrant latest news via APIs

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 – -- Announced initial data from Phase 2a clinical trial evaluati...
  • CALENDAR OF EVENTS
  • EARNINGS RELEASES AND OPERATING RESULTS
  • NASDAQ:NAMS
  • NEWAMSTERDAM PHARMA N.V

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical c...
  • DIRECTORS AND OFFICERS
  • NASDAQ:NAMS
  • NEWAMSTERDAM PHARMA N.V
Do you have any questions?
support@eodhistoricaldata.com